Literature DB >> 25282474

Is personalized medicine achievable in obstetrics?

Sara K Quinney1, Avinash S Patil2, David A Flockhart3.   

Abstract

Personalized medicine seeks to identify the right dose of the right drug for the right patient at the right time. Typically, individualization of therapy is based on the pharmacogenomic makeup of the individual and environmental factors that alter drug disposition and response. In addition to these factors, during pregnancy, a woman's body undergoes many changes that can impact the therapeutic efficacy of medications. Yet, there is minimal research regarding personalized medicine in obstetrics. Adoption of pharmacogenetic testing into the obstetrical care is dependent on evidence of analytical validity, clinical validity, and clinical utility. Here, we briefly present information regarding the potential utility of personalized medicine for treating the obstetric patient for pain with narcotics, hypertension, and preterm labor, and discuss the impediments of bringing personalized medicine to the obstetrical clinic.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  medications; obstetrics; personalized medicine; pharmacogenetics

Mesh:

Substances:

Year:  2014        PMID: 25282474      PMCID: PMC4252827          DOI: 10.1053/j.semperi.2014.08.017

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  62 in total

1.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

2.  Pharmacogenetic study of the effects of NK2R G231E G>A and TBX21 H33Q C>G polymorphisms on asthma control with inhaled corticosteroid treatment.

Authors:  Y-M Ye; H-Y Lee; S-H Kim; Y-K Jee; S-K Lee; S-H Lee; H-S Park
Journal:  J Clin Pharm Ther       Date:  2009-12       Impact factor: 2.512

Review 3.  Creating and evaluating genetic tests predictive of drug response.

Authors:  Scott T Weiss; Howard L McLeod; David A Flockhart; M Eileen Dolan; Neal L Benowitz; Julie A Johnson; Mark J Ratain; Kathleen M Giacomini
Journal:  Nat Rev Drug Discov       Date:  2008-06-20       Impact factor: 84.694

4.  Opportunities and challenges for the NIH--an interview with Francis Collins. Interview by Robert Steinbrook.

Authors:  Francis Collins
Journal:  N Engl J Med       Date:  2009-09-16       Impact factor: 91.245

5.  Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.

Authors:  Lizania Borges Spinasse; Adalberto Rezende Santos; Philip Noel Suffys; Elizabeth Silaid Muxfeldt; Gil Fernando Salles
Journal:  Pharmacogenomics       Date:  2014-02       Impact factor: 2.533

Review 6.  Clinically available pharmacogenomics tests.

Authors:  D A Flockhart; T Skaar; D S Berlin; T E Klein; A T Nguyen
Journal:  Clin Pharmacol Ther       Date:  2009-04-15       Impact factor: 6.875

7.  A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.

Authors:  Dwight J Rouse; Deborah G Hirtz; Elizabeth Thom; Michael W Varner; Catherine Y Spong; Brian M Mercer; Jay D Iams; Ronald J Wapner; Yoram Sorokin; James M Alexander; Margaret Harper; John M Thorp; Susan M Ramin; Fergal D Malone; Marshall Carpenter; Menachem Miodovnik; Atef Moawad; Mary J O'Sullivan; Alan M Peaceman; Gary D V Hankins; Oded Langer; Steve N Caritis; James M Roberts
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245

8.  The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids.

Authors:  Gregory A Hawkins; Ross Lazarus; Richard S Smith; Kelan G Tantisira; Deborah A Meyers; Stephen P Peters; Scott T Weiss; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2009-02-28       Impact factor: 10.793

9.  A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics.

Authors:  S K Quinney; A N Mohamed; M F Hebert; D M Haas; S Clark; J G Umans; S N Caritis; L Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.

Authors:  J Pink; M Pirmohamed; S Lane; D A Hughes
Journal:  Clin Pharmacol Ther       Date:  2013-09-23       Impact factor: 6.875

View more
  4 in total

1.  Value of Genetics-informed Drug Dosing Guidance in Pregnant Women: A Needs Assessment with Obstetric Healthcare Providers at Johns Hopkins.

Authors:  Casey L Overby; Phillip Thompkins; Harold Lehmann; Christopher G Chute; Jeanne S Sheffield
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

Review 2.  The brain-placental axis: Therapeutic and pharmacological relevancy to pregnancy.

Authors:  Susanta K Behura; Pramod Dhakal; Andrew M Kelleher; Ahmed Balboula; Amanda Patterson; Thomas E Spencer
Journal:  Pharmacol Res       Date:  2019-10-07       Impact factor: 7.658

Review 3.  Translational Systems Pharmacology Studies in Pregnant Women.

Authors:  Sara K Quinney; Rakesh Gullapelli; David M Haas
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-12-14

4.  Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.

Authors:  Jesús Alberto Afonso Urich; Viktoria Marko; Katharina Boehm; Raymar Andreína Lara García; Dalibor Jeremic; Amrit Paudel
Journal:  Molecules       Date:  2021-10-31       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.